Financial Restatements

NeuroOne Medical Technologies Restates Q2 Results Due to Revenue Recognition Error, Reaffirms FY2026 Guidance

NeuroOne Medical Technologies Restates Q2 Results Due to Revenue Recognition Error, Reaffirms FY2026 Guidance

NeuroOne Medical Technologies will restate its fiscal second-quarter financials after an error overstated revenue by $0.5 million, but the company reaffirms its full-year product revenue guidance of at least $10.5 million.

May 22, 2026
G Mining Ventures to Restate 2024 Financials with $32 Million Accounting Adjustment

G Mining Ventures to Restate 2024 Financials with $32 Million Accounting Adjustment

G Mining Ventures Corp. will restate its 2024 financial statements due to non-cash foreign exchange adjustments, reducing net income and earnings per share without impacting operational performance or cash position.

May 13, 2025